Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8601 epicardial injection during CABG in patients with moderately impaired systolic function
2017-002690-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and coronary arteriosclerosis comparing AZD8601 epicardial injection with Placebo epicardial injection (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events. Started Sep 2017; status: completed.
02
Drugs
AZD-8601
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on 2017-002690-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002690-19.